SMS Lifesciences India soars; facility gets US FDA clearance

Haleos Labs

16/07/2025 09:34

** SMS Lifesciences India SMSL.NS soars 17% to 1,342.2 rupees; set to snap four sessions of losses

** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in Telangana gets establishment inspection report from U.S. FDA with "voluntary action indicated" (VAI)

** A VAI classification implies facility won't face any regulatory action

** SMSL, which jumped 17% prior to the news, held gains after company disclosure

** Stock set for best day since August 12, 2024

** SMSL moved above its 50-day, 100-day, 200-day simple moving avgs

** Stock sees most active session since August 12, 2024, with more than 82,000 shares traded - 70x the 30-day moving avg

** YTD, SMSL gains 13.4%

 (Reporting by Anuran Sadhu in Bengaluru)

 ((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))